Restless Genital Syndrome Induced by Milnacipran

Keita Miyake, Manabu Takaki, Shinji Sakamoto, Kiyohiro Kawada, Shinichiro Inoue, Norihito Yamada


6 被引用数 (Scopus)


Objectives Restless genital syndrome (RGS) includes discomfort, pain, numbness, vibration, restlessness, or a burning sensation involving the vagina, perineum, pelvis, penis, and proximal portion of the lower limbs in patients. The RGS has been sometimes reported in Parkinson disease. In patients without Parkinson disease, RGS is also known as persistent genital arousal disorder (PSAS), which includes uncontrollable genital arousal, with or without orgasm or genital engorgement, unrelated to sexual desire. Although withdrawal from selective serotonin reuptake inhibitors antidepressants is reported to induce PSAS, there is no report of RGS or PSAS induced by antidepressants. Methods We obtained the consent for the presentation and have not identified individuals for ethical reasons. Results We first report a woman patient with depression induced RGS by milnacipran (MLN). Conclusions We discuss the relationship with restless legs syndrome and the difference from akathisia. It is highly possible MLN affected her RGS because she experienced RGS for the first time after the dose of MLN was increased. A limitation of this report is that we stopped MLN and administered gabapentin enacarbil immediately. We should join MLN to the list of compounds suspected of inducing RGS.

ジャーナルClinical Neuropharmacology
出版ステータスPublished - 5月 1 2018

ASJC Scopus subject areas

  • 薬理学
  • 臨床神経学
  • 薬理学(医学)


「Restless Genital Syndrome Induced by Milnacipran」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。